Vanda Pharmaceuticals Inc.
HealthcareNASDAQ:VNDA · NASDAQ Global Market
-$0.23 today
Vol 1.30M · Avg 1.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-67.4%
avg -6.9%
ROIC
-43.3%
avg -6.8%
ROA
-45.1%
avg -3.6%
Analysis
ROIC is currently the strongest return metric at -43.3% versus its period average of -6.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mihael H. Polymeropoulos | Founder, President, Chief Executive Officer & Chairman of The Board | $1.84M | — | 66 | $129,791.00 | 0.22% |
Joakim Wijkstrom | Senior Vice President & Chief Marketing Officer | $900,028.00 | — | 60 | $333,469.00 | 0.55% |
Kevin Patrick Moran | Senior Vice President, Chief Financial Officer & Treasurer | $882,160.00 | — | 42 | $20,000.00 | 0.03% |
Gunther Birznieks | Senior Vice President of Business Development | $857,971.00 | — | 57 | $494,197.00 | 0.82% |
Scott L. Howell | Chief People Officer | — | — | 51 | $100,000.00 | 0.17% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$41,500.00
Sells
7
$2.86M
Net Sentiment
$2.82M
Net selling
Most Active
Polymeropoulos Mihael Hristos
2 transactions
Analysis
Insiders reported 1 buys worth $41,500.00 and 7 sells worth $2.86M over the last 12 months. That adds up to net selling of $2.82M. Polymeropoulos Mihael Hristos was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +49.8% | +11.5% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +49.8% over three years. Forward estimates point to Revenue at +11.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Who manages VNDA?
Vanda Pharmaceuticals Inc. (VNDA) lists 5 active executives. The top listed executive is Gunther Birznieks, Senior Vice President of Business Development.
Are VNDA insiders buying or selling?
Recent insider activity shows net buying of $5.77M.
Explore More
Continue the stock analysis
Jump to another research area for this company.